Logo

2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
Mar-14-2017CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyte
CRISPR Therapeutics and Casebia obtain commercial rights to MaxCyte’s cell engineering platform to develop CRISPR/Cas9-based therapies BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Md., March 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeutics and Bayer AG for developing CRISPR-based therape... 
Printer Friendly Version
Mar-10-2017CRISPR Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
On track to file CTA for lead program in Beta-thalassemia in 2017. Strong financial position to support development of pipeline and fund operations. BASEL, Switzerland and CAMBRIDGE, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics, (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the three months and full year-ended December 31, 2016 and provided a business update. “2016... 
Printer Friendly Version
Mar-02-2017CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference
BASEL, Switzerland and CAMBRIDGE, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the Annual Barclays Global Healthcare Conference on Thursday, March 16th at the Loews Miami Beach Hotel, Miami, FL. Event: Annual Barclays Global Hea... 
Printer Friendly Version
Feb-28-2017CRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and Translation
Experienced leader with extensive experience in immuno-oncology Dedicated unit in immuno-oncology to accelerate efforts BASEL, Switzerland and CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Jon Terrett, Ph.D. as Head of Immuno-Oncology Research and Translation.  Dr. Terrett brings to CRISPR Therapeutics an im... 
Printer Friendly Version
Feb-15-2017CRISPR Therapeutics to Host Conference Call and Webcast to Provide an Update on the CRISPR/Cas9 U.S. Patent Interference Proceedings and Corresponding U.K. Patents
BASEL, Switzerland and CAMBRIDGE, Mass., Feb. 15, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that management will host a conference call and live audio webcast on Thursday, February 16, 2017 at 11:00 a.m. ET to provide an update on the CRISPR/Cas9 U.S. Patent Interference Proceedings as well as an update on the corresponding U.K. patents.    ... 
Printer Friendly Version
Feb-15-2017CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.
UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells, will be released from the interference absent an appeal, and may then be prosecuted to potential issuance Additional legal channels are available to recognize the priority of the University of California/University of Vienna/Charpentier intellectual... 
Printer Friendly Version